GB9819999D0 - Treatment of cancer - Google Patents

Treatment of cancer

Info

Publication number
GB9819999D0
GB9819999D0 GBGB9819999.5A GB9819999A GB9819999D0 GB 9819999 D0 GB9819999 D0 GB 9819999D0 GB 9819999 A GB9819999 A GB 9819999A GB 9819999 D0 GB9819999 D0 GB 9819999D0
Authority
GB
United Kingdom
Prior art keywords
cancer
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9819999.5A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University College London
Original Assignee
University College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University College London filed Critical University College London
Priority to GBGB9819999.5A priority Critical patent/GB9819999D0/en
Publication of GB9819999D0 publication Critical patent/GB9819999D0/en
Priority to EP99946334A priority patent/EP1112356A1/en
Priority to PCT/GB1999/003047 priority patent/WO2000015780A1/en
Priority to JP2000570307A priority patent/JP2002525269A/en
Priority to CA002343354A priority patent/CA2343354A1/en
Priority to AU58748/99A priority patent/AU5874899A/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
GBGB9819999.5A 1998-09-14 1998-09-14 Treatment of cancer Ceased GB9819999D0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
GBGB9819999.5A GB9819999D0 (en) 1998-09-14 1998-09-14 Treatment of cancer
EP99946334A EP1112356A1 (en) 1998-09-14 1999-09-14 Inhibitor of brn-3b and its use for the treatment of breast and ovarian cancers
PCT/GB1999/003047 WO2000015780A1 (en) 1998-09-14 1999-09-14 Inhibitor of brn-3b and its use for the treatment of breast and ovarian cancer
JP2000570307A JP2002525269A (en) 1998-09-14 1999-09-14 Inhibitors of BRN-3B and their use for the treatment of breast and ovarian cancer
CA002343354A CA2343354A1 (en) 1998-09-14 1999-09-14 Inhibitor of brn-3b and its use for the treatment of breast and ovarian cancer
AU58748/99A AU5874899A (en) 1998-09-14 1999-09-14 Inhibitor of brn-3b and its use for the treatment of breast and ovarian cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9819999.5A GB9819999D0 (en) 1998-09-14 1998-09-14 Treatment of cancer

Publications (1)

Publication Number Publication Date
GB9819999D0 true GB9819999D0 (en) 1998-11-04

Family

ID=10838839

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9819999.5A Ceased GB9819999D0 (en) 1998-09-14 1998-09-14 Treatment of cancer

Country Status (6)

Country Link
EP (1) EP1112356A1 (en)
JP (1) JP2002525269A (en)
AU (1) AU5874899A (en)
CA (1) CA2343354A1 (en)
GB (1) GB9819999D0 (en)
WO (1) WO2000015780A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2206781B1 (en) 2004-06-28 2015-12-02 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
BR122020021379B1 (en) 2008-10-24 2021-05-11 Sarepta Therapeutics, Inc. morpholino phosphorodiamidate oligomer, composition comprising the same and use of said oligomer to treat muscular dystrophy
KR101958491B1 (en) 2009-11-12 2019-03-15 더 유니버시티 오브 웨스턴 오스트레일리아 Antisense Molecules and Methods for Treating Pathologies
BR112015023001B8 (en) 2013-03-14 2022-08-09 Sarepta Therapeutics Inc ANTISENSE OLIGONUCLEOTIDE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND USE OF SUCH COMPOSITION FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD)
WO2014144978A2 (en) 2013-03-15 2014-09-18 Sarepta Therapeutics, Inc. Improved compositions for treating muscular dystrophy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1003859A1 (en) * 1997-07-25 2000-05-31 Neurovex Limited Use of transcription factor brn-3a

Also Published As

Publication number Publication date
WO2000015780A1 (en) 2000-03-23
AU5874899A (en) 2000-04-03
CA2343354A1 (en) 2000-03-23
EP1112356A1 (en) 2001-07-04
JP2002525269A (en) 2002-08-13

Similar Documents

Publication Publication Date Title
GB9824436D0 (en) Methods of treatment
SI1176964T1 (en) Uses of et743 for treating cancer
GB9800942D0 (en) Well treatment
GB9811598D0 (en) Diagnosis and treatment of cancer
HUP0101947A3 (en) Combination for the treatment of tumors
IL149281A0 (en) Treatment of cancer
GB9819999D0 (en) Treatment of cancer
AU5552400A (en) Treatment of cancer
GB9804361D0 (en) Cancer treatment
GB2343629B (en) Treatment of cellulite
GB9805686D0 (en) Treatment of metals
GB0020261D0 (en) Therapeutic treatment
GB9903035D0 (en) Treating cancer
GB2334579B (en) Treating cancer
GB9911183D0 (en) Treatment of cancers
GB9818524D0 (en) Inorgasmia treatment
GB9815497D0 (en) Treatment
GB9820000D0 (en) Cancer treatment
GB9818023D0 (en) Cancer treatment
GB9911346D0 (en) Treatment of cancers
GB9927005D0 (en) Treatment of cancers
GB9918534D0 (en) Treatment of cancers
IL141880A0 (en) Treatment of depression
AUPO851597A0 (en) Treatment of prostate cancer
GB9800707D0 (en) Methods of treatment

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)